Brind.
  1. The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.
  2. Indian drug makers are targeting the North American market.
  3. India supplies 40 per cent of generic drugs consumed in the US, with government programs like Medicare procuring these drugs to cut expenditure, though tariff hikes pose a threat.

Slotkin argues Medicare should negotiate drug prices while criticizing Trump's proposed tariffs on generic drugs.

1 report, 1 independent Updated Jul 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Slotkin argues Medicare should negotiate drug prices while criticizing Trump's proposed tariffs on generic drugs.

Who's involved

What this event is mainly about
Elissa SlotkinMedicareDonald Trump

How it developed

Newest first. Tap a step to see who reported it.
  1. Tariffs are introducing uncertainty into the drug market structure.Sub-event
  2. Slotkin criticizes Trump's tariffs on generics while advocating for Medicare drug price negotiation.1 source

Keep exploring

Part of

India supplies 40 per cent of generic drugs consumed in the US, with government programs like Medicare procuring these drugs to cut expenditure, though tariff hikes pose a threat. All 1 developments

Within The generic drug market is seeing significant growth, driven by Indian firms and regional markets, with major players like Aurobindo, J&J, and GSK involved.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • benzinga.comElissa Slotkin Warns Trump's Generic Drug Tariffs Risk Raising Prescription Costs: 'You, the Customer, Wi